BlackRock’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

BlackRock’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-456,689	Closed	-$827K	–	5584
2023 Q2	$827K	Sell	456,689 -1,423,653	-76%	-$2.6M	﹤0.01%	4334
2023 Q1	$2.48M	Sell	1,880,342 -49,003	-3%	-$80.1K	﹤0.01%	3949
2022 Q4	$3.26M	Buy	1,929,345 +55,582	+3%	+$70.4K	﹤0.01%	3919
2022 Q3	$3.47M	Buy	1,873,763 +268,168	+17%	+$800K	﹤0.01%	3916
2022 Q2	$4.93M	Buy	1,605,595 +1,261,808	+367%	+$7.7M	﹤0.01%	3822
2022 Q1	$2.48M	Buy	+343,787	New	+$3.38M	﹤0.01%	4300

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

BlackRock's PRDS Position: Q3 2023 in Review

BlackRock sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 456,689 shares — an estimated $827K sold.

BlackRock first reported a position in PRDS in Q1 2022 and held it in 6 quarters. The position peaked at $4.93M in Q2 2022. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

BlackRock reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
BlackRock sold 456,689 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $827K.
BlackRock first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2022 and held it in 6 quarters.
BlackRock's Pardes Biosciences, Inc. Common Stock position peaked at $4.93M in Q2 2022.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.